The Effects of Autonomy and Perceptions on Resistance Training Outcomes

Sponsor
Tel Aviv University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05371587
Collaborator
(none)
120
1
2
24
5

Study Details

Study Description

Brief Summary

120 participants will be randomized into one of two groups that will perform resistance training at a gym three time per week for three months. One group will follow common resistance training guidelines, whereas the other will exercise according to their preferences and perception of effort. The groups will be compared on the following primary outcomes after six and 12 weeks: body composition, physiological and performance tests. The groups will be compared on the following secondary outcomes every two weeks: enjoyment and satisfaction levels. Adherence rates will be measured throughout the intervention.

Condition or Disease Intervention/Treatment Phase
  • Other: Autonomy and Perceptions Approach to Resistance Training (APART)
  • Other: Standard prescription
N/A

Detailed Description

Develop and test the non-inferiority of a new RT prescription model, entitled The Autonomy and Perceptions Approach to Resistance Training (APART). This approach is simple to follow, individualized, and autonomy supportive. Accordingly, it may assist trainees to overcome some of the limitations of the standard RT prescription approach. Under APART, trainees choose the loads they lift for each exercise according to their preferences, and then complete as many repetitions as required until reaching a specific rating of perceived effort (RPE) value on a 0 (no effort) to 10 (maximal effort) scale (e.g., 8/10). For this non-inferiority randomized controlled trial, the investigators will recruit 120 healthy, sedentary participants, between the ages of 18 and 45, who will be block-randomized by gender and age (18-27, 28-45) to either the APART or the standard groups. Following two baseline-testing sessions and two guided familiarization sessions, participants will independently complete three RT sessions per week for 12 weeks. The following primary outcomes will be assessed after six and 12 weeks: (ⅰ) body composition including fat free mass; (ⅱ) performance measures, including maximal strength and strength endurance; and (ⅲ) physiological measures, including blood profile and hemodynamics. The following secondary outcomes will be measured every two weeks: (ⅳ) psychological measures, including self-efficacy, autonomy, and enjoyment; and (ⅴ) adherence measures, which will be monitored throughout the intervention. If APART will be found to be non-inferior to the standard RT prescription, it can provide a simple and easy to follow alternative to the standard RT prescriptions, which also highlights trainees' preferences and individual abilities. This, in turn, might contribute to future participation and adherence to RT.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A parallel two-armed, non-inferiority randomized controlled trialA parallel two-armed, non-inferiority randomized controlled trial
Masking:
Single (Participant)
Masking Description:
Participants are allocated using sealed envelops, they receive their arm identification "A" or "B" without information regarding the intervention or group differences. Data will be analyzed using the identification letter without treatment allocation information.
Primary Purpose:
Treatment
Official Title:
The Effects of the Autonomy and Perceptions Approach to Resistance Training (APART) on Body Composition, Physiological and Performance Outcomes in Healthy Young Adults: a Non-inferiority Randomized Controlled Trial
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: A - Standard resistance training prescription

Standard resistance training prescription: participants will perform three sessions per week comprised of six resistance training exercises - horizontal leg press, lat-pulldown, knee extension, chest press, leg curls and shoulder press. They will perform 3 sets of 10 repetitions using 65% percent of the maximal load that can be lifted once according to a one repetition maximum (1RM) test. Their progression model will be as follows: Weeks 1-3 65%1RM; Weeks 4-6 70%1RM; 1RM reassessment at week 6; Weeks 7-9 70% of the updated 1RM; Weeks 10-12 75%1RM. Prior to beginning of the program four visits will take place: Laboratory visit for measuring physiological and anthropometric outcomes (see outcomes section) 1RM testing Endurance and maximal voluntary contraction testing + introduction with the exercise program A second introduction session with the exercise program

Other: Standard prescription
Standard resistance training prescription, based on international organization's guidelines.

Experimental: B- Autonomy and perceptions approach to resistance training (APART)

Participants will perform 3 sessions/week of the same exercises. They will perform 3 sets of each exercise, self-select the load they lift in each set and perform repetitions aiming to reach a level of effort of 7-8 on a 0-10 rating of perceived effort scale (RPE) at the end of the set. Their progression model will be as follows: Weeks 1-3 RPE 7/10; Weeks 4-12 RPE 8/10. The selected RPE score of 7 and then 8 out of 10 has been shown to lead to increases in maximal strength in previous research. Prior to beginning of the program four visits will take place: Laboratory visit (similar to standard). 1RM testing where the principles of perceived effort will be introduced. Endurance and maximal voluntary contraction testing + introduction with the exercise program. Participants will practice how to self-select the load they prefer and then perform repetitions leading to the target RPE score. A second introduction session with the exercise program and the RPE construct.

Other: Autonomy and Perceptions Approach to Resistance Training (APART)
Alternative resistance training prescription based on trainees' autonomy and perceptions.

Outcome Measures

Primary Outcome Measures

  1. Change in fat free mass [Baseline to six weeks]

    Fat free mass will be measured using the SECA mBCA 515 (Seca, Hamburg, Germany), a valid and reliable analyzer of body composition. Participants will drink 400 ml of water before the examination which will take place in the morning. Drinking will be stopped 30 minutes before the examination and participants will be instructed to urinate and remove any jewelries before the examination.

  2. Change in fat free mass [Six weeks to 12 weeks]

    Fat free mass will be measured using the SECA mBCA 515 (Seca, Hamburg, Germany), a valid and reliable analyzer of body composition. Participants will drink 400 ml of water before the examination which will take place in the morning. Drinking will be stopped 30 minutes before the examination and participants will be instructed to urinate and remove any jewelries before the examination.

  3. Change in total cholesterol value [Baseline to six weeks]

    The blood samples will be collected by single-use disposable needle. A total of 20 mL of blood will be collected at each time-point in two, 10 mL Vacutainer® tubes: a plasma tube containing anticoagulant and a serum tube where the blood is allowed to clot. Plasma samples will be stored in ice until centrifuged twice at 1,500g for 10 minutes at 4° Celsius. Serum will be kept in room temperature for 60 minutes then centrifuged at 1300g for 10 minutes. Both samples will be divided into separate 1.8-mL microcentrifuge tubes and will be frozen at -80° C for later analysis

  4. Change in total cholesterol value [Six weeks to 12 weeks]

    The blood samples will be collected by single-use disposable needle. A total of 20 mL of blood will be collected at each time-point in two, 10 mL Vacutainer® tubes: a plasma tube containing anticoagulant and a serum tube where the blood is allowed to clot. Plasma samples will be stored in ice until centrifuged twice at 1,500g for 10 minutes at 4° Celsius. Serum will be kept in room temperature for 60 minutes then centrifuged at 1300g for 10 minutes. Both samples will be divided into separate 1.8-mL microcentrifuge tubes and will be frozen at -80° C for later analysis

  5. Change in fasting glucose value [Baseline to six weeks]

    The blood samples will be collected by single-use disposable needle. A total of 20 mL of blood will be collected at each time-point in two, 10 mL Vacutainer® tubes: a plasma tube containing anticoagulant and a serum tube where the blood is allowed to clot. Plasma samples will be stored in ice until centrifuged twice at 1,500g for 10 minutes at 4° Celsius. Serum will be kept in room temperature for 60 minutes then centrifuged at 1300g for 10 minutes. Both samples will be divided into separate 1.8-mL microcentrifuge tubes and will be frozen at -80° C for later analysis

  6. Change in fasting glucose value [Six weeks to 12 weeks]

    The blood samples will be collected by single-use disposable needle. A total of 20 mL of blood will be collected at each time-point in two, 10 mL Vacutainer® tubes: a plasma tube containing anticoagulant and a serum tube where the blood is allowed to clot. Plasma samples will be stored in ice until centrifuged twice at 1,500g for 10 minutes at 4° Celsius. Serum will be kept in room temperature for 60 minutes then centrifuged at 1300g for 10 minutes. Both samples will be divided into separate 1.8-mL microcentrifuge tubes and will be frozen at -80° C for later analysis

  7. Change in systolic blood pressure [Baseline to six weeks]

    Participants will rest in a relaxed seating position for five minutes. Then their blood pressure and resting heart rate will be taken using an Omron M7 (HEM-780-E) blood pressure measuring device.

  8. Change in systolic blood pressure [Six weeks to 12 weeks]

    Participants will rest in a relaxed seating position for five minutes. Then their blood pressure and resting heart rate will be taken using an Omron M7 (HEM-780-E) blood pressure measuring device.

  9. Change in diastolic blood pressure [Baseline to six weeks]

    Participants will rest in a relaxed seating position for five minutes. Then their blood pressure and resting heart rate will be taken using an Omron M7 (HEM-780-E) blood pressure measuring device.

  10. Change in diastolic blood pressure [Six weeks to 12 weeks]

    Participants will rest in a relaxed seating position for five minutes. Then their blood pressure and resting heart rate will be taken using an Omron M7 (HEM-780-E) blood pressure measuring device.

  11. Change in maximal muscle strength- One repetition maximum [Baseline to six weeks]

    Participants will perform a dynamic warmup including mobility and calisthenics exercises, followed by specific warm up sets of each of the six exercises. Then, up to five attempts will be made to complete one repetition sets with increasing load until the participant either fails to complete the full range of motion or declares she cannot attempt the next set. The load (in kg) of the final successful attempt for each exercise will be documented for analysis. Two to three minutes rest will be provided between the attempts. The order of the exercises will be maintained throughout the assessment points and between participants. The assessments will be carried out by the same experimenter at the same time of day ±2 hours.

  12. Change in maximal muscle strength- One repetition maximum [Six weeks to 12 weeks]

    Participants will perform a dynamic warmup including mobility and calisthenics exercises, followed by specific warm up sets of each of the six exercises. Then, up to five attempts will be made to complete one repetition sets with increasing load until the participant either fails to complete the full range of motion or declares she cannot attempt the next set. The load (in kg) of the final successful attempt for each exercise will be documented for analysis. Two to three minutes rest will be provided between the attempts. The order of the exercises will be maintained throughout the assessment points and between participants. The assessments will be carried out by the same experimenter at the same time of day ±2 hours.

  13. Change in muscle endurance [Baseline to six weeks]

    Participants will perform a dynamic warmup including mobility and calisthenics exercises, followed by specific warm up sets of the knee extension and the chest press exercises. Then, 70% of the participant's identified maximal load (1RM) will be used to perform repetitions until task-failure (i.e., not able to complete another repetition). The number of completed repetitions will be documented for analysis. The same reference load will be used at six weeks. The order of the exercises will be maintained throughout the assessment points and between participants. The assessments will be carried out by the same experimenter at the same time of day ±2 hours.

  14. Change in muscle endurance [Six weeks to 12 weeks]

    Participants will perform a dynamic warmup including mobility and calisthenics exercises, followed by specific warm up sets of the knee extension and the chest press exercises. Then, 70% of the participant's identified maximal load (1RM) will be used to perform repetitions until task-failure (i.e., not able to complete another repetition). The number of completed repetitions will be documented for analysis. The same reference load will be used at 12 weeks. The order of the exercises will be maintained throughout the assessment points and between participants. The assessments will be carried out by the same experimenter at the same time of day ±2 hours.

  15. Change in maximum voluntary contraction (MVC) - knee extension [Baseline to six weeks]

    Isometric knee extension (using the knee extension machine) - will be assessed in a 90° angle using a link device (Kinvent, Link pull dynamometer) attached to a ratchet belt.

  16. Change in maximum voluntary contraction (MVC) - knee extension [Six weeks to 12 weeks]

    Isometric knee extension (using the knee extension machine) - will be assessed in a 90° angle using a link device (Kinvent, Link pull dynamometer) attached to a ratchet belt.

  17. Change in maximum voluntary contraction (MVC) - horizontal row [Baseline to six weeks]

    Isometric horizontal row will be assessed in a 60° elbow flexion angle on the T-bar machine (Nautilus, WA, USA). The same link device will be secured using ratchet belts to match the desired setup for each participant.

  18. Change in maximum voluntary contraction (MVC) - horizontal row [Six weeks to 12 weeks]

    Isometric horizontal row will be assessed in a 60° elbow flexion angle on the T-bar machine (Nautilus, WA, USA). The same link device will be secured using ratchet belts to match the desired setup for each participant.

Secondary Outcome Measures

  1. Change in self efficacy questionnaire score [Baseline to six weeks]

    The self-efficacy questionnaire is an eight items questionnaire. Respondents are required to read the statements and rate their level of agreement with each statement on a three points Likert scale. Score-range is 8-24. Higher scores indicate higher levels of self-efficacy.

  2. Change in self efficacy questionnaire score [Six weeks to 12 weeks]

    The self-efficacy questionnaire is an eight items questionnaire. Respondents are required to read the statements and rate their level of agreement with each statement on a three points Likert scale. Score-range is 8-24. Higher scores indicate higher levels of self-efficacy.

  3. Enjoyment [Two weeks]

    Every other week during the 12 weeks of the intervention, participants will respond to an online survey examining their levels of enjoyment from the training sessions via a bi-polar scale ranging from -50 ("did not enjoy at all") to 50 ("extremely enjoyed").

  4. Enjoyment [Four weeks]

    Every other week during the 12 weeks of the intervention, participants will respond to an online survey examining their levels of enjoyment from the training sessions via a bi-polar scale ranging from -50 ("did not enjoy at all") to 50 ("extremely enjoyed").

  5. Enjoyment [Eight weeks]

    Every other week during the 12 weeks of the intervention, participants will respond to an online survey examining their levels of enjoyment from the training sessions via a bi-polar scale ranging from -50 ("did not enjoy at all") to 50 ("extremely enjoyed").

  6. Enjoyment [Ten weeks]

    Every other week during the 12 weeks of the intervention, participants will respond to an online survey examining their levels of enjoyment from the training sessions via a bi-polar scale ranging from -50 ("did not enjoy at all") to 50 ("extremely enjoyed").

  7. Adherence [End of week 12]

    Number of entries to the gym, documented by the gym front desk

  8. Adherence without incentive [From week 12 to week 16]

    Number of entries to the gym, documented by the gym front desk

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • No health issues preventing resistance training

  • Body mass index (BMI) between 18.5 ("normal") and 29.9 ("overweight")

  • Body weight > 50 Kg

  • Without RT experience or with little experience (i.e. less than once a week in the past 12 months).

Exclusion Criteria:
  • Participants who responded positively to any of the health sections and did not provide medical clearance

  • Pregnant women or less than six months after childbirth

  • BMI values outside of the specified range

  • Body weight < 50 Kg

  • RT experience exceeding the specified cut-off (see above)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tel Aviv University Tel Aviv Israel 4059100

Sponsors and Collaborators

  • Tel Aviv University

Investigators

  • Principal Investigator: Israel Halperin, PhD, Tel Aviv University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Israel Halperin, Principle investigator, Tel Aviv University
ClinicalTrials.gov Identifier:
NCT05371587
Other Study ID Numbers:
  • ISF_Halperin_TAU
First Posted:
May 12, 2022
Last Update Posted:
May 19, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Israel Halperin, Principle investigator, Tel Aviv University

Study Results

No Results Posted as of May 19, 2022